PT  - JOURNAL ARTICLE
AU  - Arthur Schafer
TI  - Institutional conflict of interest: attempting to crack the deferiprone mystery
AID  - 10.1136/medethics-2019-105498
DP  - 2020 Jan 08
TA  - Journal of Medical Ethics
PG  - medethics-2019-105498
4099  - http://jme.bmj.com/content/early/2020/01/16/medethics-2019-105498.short
4100  - http://jme.bmj.com/content/early/2020/01/16/medethics-2019-105498.full
AB  - A recent study by Olivieri et al, published in PLOS ONE, reports that between 2009 and 2015 a third of patients with thalassaemia in Canada’s largest hospital were switched from first-line licensed drugs to regimens of deferiprone, an unlicensed drug of unproven safety and efficacy. Based on retrospective data from patient records, the PLOS Study reports that patients treated with deferiprone, either as monotherapy or in combination with first-line drugs, suffered serious (and often irreversible) adverse effects. The data reported by Olivieri et al give rise to a number of ethical issues. These ethical issues are identified, placed in historical context and analysed. For purposes of this analysis, reliance is placed on two core principles of research ethics, harm minimisation and informed consent, and also on the hospital’s mission statement. Then a mystery is explored: How and why did it happen that Toronto’s University Health Network treated large numbers of patients with an unlicensed drug over a period of many years? ‘Institutional conflict of interest’ is considered as a possible explanatory hypothesis.